GNTA Stock Analysis: Buy, Sell, or Hold?
GNTA - Genenta Science S.p.A. American Depositary Shares
$1.25
-0.07 (-5.30%)
▼
5d:
-22.36%
30d:
-34.9%
90d:
+94.52%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Mar 27, 2026
0d
Get Alerted When GNTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GNTA is down 22.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GNTA is down 22.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GNTA is currently trading at $1.25, which is considered oversold relative to its 30-day fair value range of $1.54 to $1.88.
Technical Outlook: Technically, GNTA is showing sideways momentum. Immediate support is located at $0.57, while resistance sits at $2.58. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.98 (+458.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GNTA is showing sideways momentum. Immediate support is located at $0.57, while resistance sits at $2.58. Short-term momentum is weak, with the stock down 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $6.98 (+458.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.54 -
$1.88
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.3%)
- BULLISH: Trading 458.4% below Wall St target ($6.98)
- WARNING: Recommendation downgraded due to -22.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.54 -
$1.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.57
Resistance Level
$2.58
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.36
Wall Street Target
$6.98
(+458.4%)
Share & Embed Analysis
Last updated: July 15, 2026 3:15 AM ET
Data refreshes hourly during market hours. Next update: 4:15 AM
Data refreshes hourly during market hours. Next update: 4:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GNTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
